[Featured Stock] Helixmith, Engensis Gains Attention Abroad Again... Will It Recapture Former Glory?

[Asia Economy Reporter Hyungsoo Park] Helixmith's stock price is soaring. The news that the first US Phase 3 clinical trial (3-1 phase, 3-1b phase) study of Enzensus (VM202) for diabetic peripheral neuropathy (DPN) was selected as a 'Notable Clinical Result of Q1 2021' by the international journal Nature Biotechnology appears to have influenced the stock price.

At 10:19 AM on the 8th, Helixmith was trading at 34,100 KRW, up 12.17% from the previous day.

Previously, Helixmith's stock price plummeted as the Enzensus clinical results fell short of expectations. In September 2019, when expectations for Enzensus were high, Helixmith's stock price even exceeded 150,000 KRW.

Nature Biotechnology selected a total of 10 papers. The company stated that many of the achievements were published in world-renowned medical journals such as The New England Journal of Medicine and The Lancet.

The Enzensus DPN study results published by Helixmith in January in the international medical journal Clinical and Translational Science were selected. This was the world's first Phase 3 clinical trial of gene therapy for pain. In the paper, clinical researchers reported the high safety of Enzensus, and especially in the 3-1b phase, excellent efficacy. It was explained that the treatment effect was even better in patients who could not use existing drugs. Furthermore, the drug's effect lasted for 8 months after the drug disappeared, suggesting that Enzensus can fundamentally treat DPN.

Nature Biotechnology is an international journal in the field of biotechnology published monthly by Nature. Every quarter, it selects and announces notable cases such as new drug approvals and clinical trial result announcements.

This content was produced with the assistance of AI translation services.